155 related articles for article (PubMed ID: 36329604)
1. Single-Step and Highly Sensitive Imaging of Exosomal PD-L1 through Aptamer-Activated Cascade Primer Exchange Reaction-Generated Branched DNA Nanostructures.
Li X; Li X; Cheng X; Bian X; Shen B; Ding X; Ding S
ACS Sens; 2022 Nov; 7(11):3571-3579. PubMed ID: 36329604
[TBL] [Abstract][Full Text] [Related]
2. Tracing Tumor-Derived Exosomal PD-L1 by Dual-Aptamer Activated Proximity-Induced Droplet Digital PCR.
Lin B; Tian T; Lu Y; Liu D; Huang M; Zhu L; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2021 Mar; 60(14):7582-7586. PubMed ID: 33382182
[TBL] [Abstract][Full Text] [Related]
3. Sensitive Detection of Exosomal Proteins via a Compact Surface Plasmon Resonance Biosensor for Cancer Diagnosis.
Liu C; Zeng X; An Z; Yang Y; Eisenbaum M; Gu X; Jornet JM; Dy GK; Reid ME; Gan Q; Wu Y
ACS Sens; 2018 Aug; 3(8):1471-1479. PubMed ID: 30019892
[TBL] [Abstract][Full Text] [Related]
4. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
[TBL] [Abstract][Full Text] [Related]
5. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
6. Exosomal PD-L1 predicts response with immunotherapy in NSCLC patients.
Wang Y; Niu X; Cheng Y; Zhang Y; Xia L; Xia W; Lu S
Clin Exp Immunol; 2022 Jun; 208(3):316-322. PubMed ID: 35514075
[TBL] [Abstract][Full Text] [Related]
7. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
[TBL] [Abstract][Full Text] [Related]
8. Nanoplasmonic Sandwich Immunoassay for Tumor-Derived Exosome Detection and Exosomal PD-L1 Profiling.
Wang C; Huang CH; Gao Z; Shen J; He J; MacLachlan A; Ma C; Chang Y; Yang W; Cai Y; Lou Y; Dai S; Chen W; Li F; Chen P
ACS Sens; 2021 Sep; 6(9):3308-3319. PubMed ID: 34494426
[TBL] [Abstract][Full Text] [Related]
9. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
10. Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy.
Hao J; Wang J; Dong Y; Yang J; Wang Z; Zhao X; Zeng T; Zhao X; Liang H; Li J
Anal Chem; 2023 May; 95(17):6854-6862. PubMed ID: 37027485
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
12. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
13. Accurate Cancer Screening and Prediction of PD-L1-Guided Immunotherapy Efficacy Using Quantum Dot Nanosphere Self-Assembly and Machine Learning.
Zhang YP; Chen HJ; Hu Y; Lin L; Wen HY; Pang DW; Zhang S; Wang ZG; Liu SL
Nano Lett; 2024 Feb; 24(5):1816-1824. PubMed ID: 38270101
[TBL] [Abstract][Full Text] [Related]
14. Personalized detection of circling exosomal PD-L1 based on Fe
Pang Y; Shi J; Yang X; Wang C; Sun Z; Xiao R
Biosens Bioelectron; 2020 Jan; 148():111800. PubMed ID: 31678824
[TBL] [Abstract][Full Text] [Related]
15. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
16. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
17. The Biogenesis, Biology, and Clinical Significance of Exosomal PD-L1 in Cancer.
Tang Y; Zhang P; Wang Y; Wang J; Su M; Wang Y; Zhou L; Zhou J; Xiong W; Zeng Z; Zhou Y; Nie S; Liao Q
Front Immunol; 2020; 11():604. PubMed ID: 32322256
[TBL] [Abstract][Full Text] [Related]
18. The Importance of Exosomal PD-L1 in Cancer Progression and Its Potential as a Therapeutic Target.
Ye L; Zhu Z; Chen X; Zhang H; Huang J; Gu S; Zhao X
Cells; 2021 Nov; 10(11):. PubMed ID: 34831468
[TBL] [Abstract][Full Text] [Related]
19. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P
J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383
[TBL] [Abstract][Full Text] [Related]
20. Simultaneous detection of cancerous exosomal miRNA-21 and PD-L1 with a sensitive dual-cycling nanoprobe.
Qin X; Xiang Y; Li N; Wei B; Chen Y; Fang D; Fang M; Li Q; Liu J; Tang Y; Li X; Yang F
Biosens Bioelectron; 2022 Nov; 216():114636. PubMed ID: 35986985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
